Q3 Revenue Jumps 14% to $50.2M, Guidance Raised to $197-199M
CYRX has more than doubled off its 52-week low of $7.61 on elevated volume (2.2× avg).
Summary
Cryoport beat its own trajectory with Q3 revenue of $50.2 million, up 14% year-over-year from $44.2 million, accelerating from the 7.7% growth reported in Q2 and topping the IBES estimate of USD 48.8 million. Commercial cell and gene therapy revenue rose 20% and BioStorage/BioServices grew 25%, while the company posted positive adjusted EBITDA of $1.1 million versus negative $0.6 million a year ago — its first meaningful step toward profitability. Management raised full-year 2026 revenue guidance to $197-199 million, and the company now supports a record 788 clinical trials and 23 commercial therapies. The offset: net loss widened to $10.9 million from $6.9 million, driven largely by a $4.2 million unrealized loss on investments, and gross margin slipped to 47.5% from 48.2% on weaker product margins. With $393.1 million in cash and short-term investments, the balance sheet is not a near-term concern.
At the time of this announcement, CYRX was trading at $16.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $812.9M. The 52-week trading range was $7.61 to $18.88. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.